A report by Chung et al. evaluated the performance of the QXDx BCR::ABL1 %IS (Bio-Rad, Hercules, CA, USA) droplet digital PCR (ddPCR) assay—the first commercially available tool of its type—and found a very strong correlation between this assay and the real-time PCR ipsogen BCR::ABL1 Mbcr IS-MMR (Qiagen, Hilden, Germany), suggesting that dPCR can provide reliable results for CML patients [65]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.